Products for Research Use Only
RegisterLogin

Decitabine (Standard)

CAT: 0804-HY-A0004R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0004R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Decitabine (Standard) is the analytical standard of Decitabine. This product is intended for research and analytical applications. Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].
CAS Number
2353-33-5
Product Name Alternative
5-Aza-2'-deoxycytidine (Standard) ; 5-AZA-CdR (Standard) ; NSC 127716 (Standard)
UNSPSC
12352005
Target
Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog; Reference Standards
Type
Reference Standards
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/decitabine-standard.html
Purity
99.91
Smiles
O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
Molecular Formula
C8H12N4O4
Molecular Weight
228.21
References & Citations
[1]Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates E-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2016 Jul 19.|[2]Hagemann S, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011 Mar 7;6 (3) :e17388.|[3]Requena CE, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016 Jun 20.|[4]Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33 (2) :75-85.|[5]Yu J, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018 Jun 1;128 (6) :2376-2388.|[6]Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumorspecific cytotoxic T lymphocyte responses. PLoS One. 2013 May 9;8 (5) :e62924.|[7]Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009 Jul;109 (7) :2880-93.
Shipping Conditions
Room Temperature
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards
Clinical Information
Launched

Related Products

CatalogName
HY-A0004-01Decitabine
HY-W767228Decitabine-15N4
HY-A0004SDecitabine-13C5
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)

Alternative Products

CatalogName
167170α-Decitabine
abx076551-01Decitabine

Popular Products